Topiramate for pediatric migraine prevention

Teeranai Sakulchit, Garth D. Meckler, Ran D. Goldman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Question I have several teenagers in my clinic with migraine headache and some of them have frequent episodes that cause considerable interference with daily activity. I would like to offer them prophylactic therapy to reduce the frequency of their migraine episodes. Is topiramate an effective and safe option for adolescents? Answer Both Health Canada and the US Food and Drug Administration have approved the use of topiramate for migraine prevention in adults; however, only the US Food and Drug Administration has approved topiramate for migraine prophylaxis in adolescents 12 to 17 years of age. Although several studies support its effectiveness in preventing migraine, most of these studies are small; and a recent large multicentre, randomized placebo-controlled trial was stopped early when no benefit was shown over placebo. Adverse effects of topiramate are mild and typically resolve over time. The recommended dosage is 2 mg/kg per day, up to an adult dose of 100 mg/d.

Original languageEnglish (US)
Pages (from-to)529-535
Number of pages7
JournalCanadian Family Physician
Volume63
Issue number7
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Family Practice

Fingerprint Dive into the research topics of 'Topiramate for pediatric migraine prevention'. Together they form a unique fingerprint.

Cite this